Abstract 2342P
Background
Single tumor cells (STCs) are a manifestation of intratumor morphological heterogeneity and most likely arise from multicellular tumor structures as a result of cancer invasion. In recent years, the appearance of STCs has been described as tumor budding in the invasive front. However, there are no clear data on the clinical significance of these cells in breast cancer patients.
Methods
The study included 230 patients diagnosed with invasive breast carcinoma of the nonspecific type, luminal molecular subtypes. H&E staining was used to detect STCs in breast tissue. STCs (or detached individual tumor cells) were detected in the entire tumor tissue in contrast to tumor buds located in the invasive front, and were defined as tumor cells located outside multicellular tumor structures but similar to them in cytological features. 7-color immunofluorescence analysis was used to study the population composition of the microenvironment (ME) of STCs. Laser microdissection of STCs ME and sequencing on NextSeq500 (Illumina, USA) was performed.
Results
Patients who had a STCs had a 5.8-fold increased risk (CI95% 2.4-14.1) of developing distant metastases compared to patients who did not have a STCs (p=0.0001). Patients who had no STCs had a better metastatic-free survival (91.8%) than patients who had a STCs (49.1) (p<0.0001). The relative risk of distant metastases in breast cancer patients where only Th2-like immune reaction is found in the ME is 2.37 (CI95% 1.25-4.42) times higher than in patients where only Th1-like immune reaction (p=0.0352). In addition, a Top 10 analysis of up- and downregulated genes in the STCs ME in breast cancer patients depending on the status of distant metastasis was performed. Decrease of CD52 (7-fold), NUDT3 (6-fold), TAP1 (6-fold) (p<0.001) genes expression and increase of LAMA5 (4-fold), LPCAT1 (5-fold), FLVCR1 (5-fold) (p<0.001) genes expression were detected in the STCs ME of breast cancer patients with distant metastases compared to those without.
Conclusions
A novel simple prognostic criterion for predicting breast cancer metastasis has been developed. The microenvironment has been shown to play an important role in the metastatic potential of a single tumour cells. Immunosignatures of the pro-tumour microenvironment have been identified.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tomsk National Research Medical Center.
Funding
The study was supported by the Russian Science Foundation (grant #23-15-00135).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2222P - Frequent TERT gains in metastatic papillary thyroid carcinoma
Presenter: Sara Gil
Session: Poster session 16
2223P - Next-generation sequencing enables identification of RET rearrangements in papillary thyroid cancer
Presenter: Sergi Clavé
Session: Poster session 16
2224P - Identifying prognostic factors in patients with radioiodine-refractory differentiated thyroid carcinoma (RR-DTC) treated with tyrosine kinase inhibitors (TKI): Data from REGETNE registry
Presenter: Maria Victoria San Roman Gil
Session: Poster session 16
2225P - FOX1 (rs965513), NKX2-1 (rs944289) and BRAF (V600E) gene mutations and their role in development of papillary thyroid cancer
Presenter: Darko Katalinic
Session: Poster session 16
2226P - Survival benefit of radioiodine therapy (RAI) in papillary thyroid cancer variants (PTCV): A SEER analysis
Presenter: Sakhr Alshwayyat
Session: Poster session 16
2227P - The efficacy and safety of lenvatinib in neoadjuvant therapy in patients with locally advanced thyroid cancer: A single-arm phase II clinical trial
Presenter: Jianhong Yu
Session: Poster session 16
2228P - Long-term clinical outcomes of Lenvatinib in patients with differentiated thyroid cancer: Results from the real-world practice of a single institution
Presenter: Ryutaro Onaga
Session: Poster session 16
2229P - Updated safety and efficacy of selpercatinib in patients (pts) with RET-activated thyroid cancer: Data from LIBRETTO-001
Presenter: Lori Wirth
Session: Poster session 16
2323P - Multi-omic spatial phenotyping of the NSCLC tumour microenvironment for the development of a spatial score associated with immunotherapy resistance
Presenter: Arutha Kulasinghe
Session: Poster session 16
2324P - Trametinib and PD-1 combined blockade impairs tumor growth and improves survival of KRAS-mutant lung cancer through Id1 downregulation
Presenter: Ander Puyalto
Session: Poster session 16